Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis
Background: Differential diagnosis of Alzheimer’s disease (AD) is a complex task due to the clinical similarity among neurodegenerative diseases. Previous studies showed the role of lipid peroxidation in early AD development. However, the clinical validation of potential specific biomarkers in minim...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/9/8/649 |
| _version_ | 1797561629042278400 |
|---|---|
| author | Carmen Peña-Bautista Lourdes Álvarez Thierry Durand Claire Vigor Ana Cuevas Miguel Baquero Máximo Vento David Hervás Consuelo Cháfer-Pericás |
| author_facet | Carmen Peña-Bautista Lourdes Álvarez Thierry Durand Claire Vigor Ana Cuevas Miguel Baquero Máximo Vento David Hervás Consuelo Cháfer-Pericás |
| author_sort | Carmen Peña-Bautista |
| collection | DOAJ |
| description | Background: Differential diagnosis of Alzheimer’s disease (AD) is a complex task due to the clinical similarity among neurodegenerative diseases. Previous studies showed the role of lipid peroxidation in early AD development. However, the clinical validation of potential specific biomarkers in minimally invasive samples constitutes a great challenge in early AD diagnosis. Methods: Plasma samples from participants classified into AD (<i>n</i> = 138), non-AD (including MCI and other dementias not due to AD) (<i>n</i> = 70) and healthy (<i>n</i> = 50) were analysed. Lipid peroxidation compounds (isoprostanes, isofurans, neuroprostanes, neurofurans) were determined by ultra-performance liquid chromatography coupled with tandem mass spectrometry. Statistical analysis for biomarkers’ clinical validation was based on Elastic Net. Results: A two-step diagnosis model was developed from plasma lipid peroxidation products to diagnose early AD specifically, and a bootstrap validated AUC of 0.74 was obtained. Conclusion: A promising AD differential diagnosis model was developed. It was clinically validated as a screening test. However, further external validation is required before clinical application. |
| first_indexed | 2024-03-10T18:17:37Z |
| format | Article |
| id | doaj.art-1ad5dcae42c949e9a6801d9ead745515 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-10T18:17:37Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-1ad5dcae42c949e9a6801d9ead7455152023-11-20T07:35:10ZengMDPI AGAntioxidants2076-39212020-07-019864910.3390/antiox9080649Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential DiagnosisCarmen Peña-Bautista0Lourdes Álvarez1Thierry Durand2Claire Vigor3Ana Cuevas4Miguel Baquero5Máximo Vento6David Hervás7Consuelo Cháfer-Pericás8Neonatal Research Unit, Health Research Institute La Fe, 46026 Valencia, SpainNeurology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, SpainInstitut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS ENSCM, 34093 Montpellier, FranceInstitut des Biomolécules Max Mousseron, IBMM, University of Montpellier, CNRS ENSCM, 34093 Montpellier, FranceNeurology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, SpainNeurology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, SpainNeonatal Research Unit, Health Research Institute La Fe, 46026 Valencia, SpainBiostatistical Unit, Health Research Institute La Fe, 46026 Valencia, SpainNeonatal Research Unit, Health Research Institute La Fe, 46026 Valencia, SpainBackground: Differential diagnosis of Alzheimer’s disease (AD) is a complex task due to the clinical similarity among neurodegenerative diseases. Previous studies showed the role of lipid peroxidation in early AD development. However, the clinical validation of potential specific biomarkers in minimally invasive samples constitutes a great challenge in early AD diagnosis. Methods: Plasma samples from participants classified into AD (<i>n</i> = 138), non-AD (including MCI and other dementias not due to AD) (<i>n</i> = 70) and healthy (<i>n</i> = 50) were analysed. Lipid peroxidation compounds (isoprostanes, isofurans, neuroprostanes, neurofurans) were determined by ultra-performance liquid chromatography coupled with tandem mass spectrometry. Statistical analysis for biomarkers’ clinical validation was based on Elastic Net. Results: A two-step diagnosis model was developed from plasma lipid peroxidation products to diagnose early AD specifically, and a bootstrap validated AUC of 0.74 was obtained. Conclusion: A promising AD differential diagnosis model was developed. It was clinically validated as a screening test. However, further external validation is required before clinical application.https://www.mdpi.com/2076-3921/9/8/649plasmalipid peroxidationAlzheimer’s diseasedifferential diagnosisclinical validation |
| spellingShingle | Carmen Peña-Bautista Lourdes Álvarez Thierry Durand Claire Vigor Ana Cuevas Miguel Baquero Máximo Vento David Hervás Consuelo Cháfer-Pericás Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis Antioxidants plasma lipid peroxidation Alzheimer’s disease differential diagnosis clinical validation |
| title | Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis |
| title_full | Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis |
| title_fullStr | Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis |
| title_full_unstemmed | Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis |
| title_short | Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer’s Disease Differential Diagnosis |
| title_sort | clinical utility of plasma lipid peroxidation biomarkers in alzheimer s disease differential diagnosis |
| topic | plasma lipid peroxidation Alzheimer’s disease differential diagnosis clinical validation |
| url | https://www.mdpi.com/2076-3921/9/8/649 |
| work_keys_str_mv | AT carmenpenabautista clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT lourdesalvarez clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT thierrydurand clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT clairevigor clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT anacuevas clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT miguelbaquero clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT maximovento clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT davidhervas clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis AT consuelochaferpericas clinicalutilityofplasmalipidperoxidationbiomarkersinalzheimersdiseasedifferentialdiagnosis |